Get started
Revive Therapeutics Ltd.RR

Revive Therapeutics Ltd.

No trades
See on Supercharts
Overview Financials News
Ideas
Discussions Technicals Seasonals

RVVTF trade ideas

Revive Therapetics Canada Sun Storm Investment Trading Desk & NexGen Wealth Management Service Present's: SSITD & NexGen Portfolio of the Week Series Focus: Worldwide By Sun Storm Investment Research & NexGen Wealth Management Service A Profit & Solutions Strategy & Research Trading | Investment | Stocks | ETF | Mutual Funds | Crypto | Bonds | Options | Dividend | Futures | USA | Canada | UK | Germany | France | Italy | Rest of Europe | Mexico | India Disclaimer: Sun Storm Investment and NexGen are not registered financial advisors, so please do your own research before trading & investing anything. This is information is for only research purposes not for actual trading & investing decision. #debadipb #profitsolutions
CSE:RVV
by Sunstorminvest
Daily oversold bounceFor those who had taken profit or still waiting on the sidelines to get back into this bad boy, well here is your chance. We have just hit daily oversold conditions into an area of support and the rsi as crossed the 30 line. indicating a signal to go long. on the 65 minute timeframe we can also see a lot of bullish divergence. 0.240 would be a good target for a scalp , but this also still has potential for it's covid treatment. It's quite a volatile little thing so this isn't for the feint of heart :)
CLong
by gNnairdA
6
Swing/Long on RVVRVV is picking up some traction, one thing I notice about RVV is that the share price is directly correlated to the MACD indicator. You will see above that if you bought and the cross over to the upside, and sold at the crossover to the downside, you would be doing consistently well. RVV is presently crossing over to the upside, indicators are bullish. Therapeutic stocks (in general) have shown a reversal wick on Thursday the 24th, which were confirmed with a reversal on the 25th. Although the stock markets did well on Friday, it remains to be seen if we are going to enter a small cycle to the upside on some od those theraputic related stocks. Check it out on Yahoo news, they have a few things going including the phase 3 of its covid 19 related study. Although this company is not only a coid 19 play at all. Good news in the next 3 weeks can really cause this one to jump!
CLong
by tsx_trader
RVV.C — FDA Phase 3 Clinical Trials Approval for COVID-19 DrugRevive Therapeutics Announces U.S. FDA Approval of Confirmatory Phase 3 Clinical Trial for Bucillamine in COVID-19 TORONTO, July 31, 2020 (GLOBE NEWSWIRE) -- Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that the U.S. Food & Drug Administration (“U.S. FDA”) has approved the Company to proceed with a randomized, double-blind, placebo-controlled confirmatory Phase 3 clinical trial protocol to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. “The FDA approval of the Phase 3 study to evaluate Bucillamine in the treatment of patients with mild-moderate COVID-19 is a tremendous milestone for Revive and I am very proud of the dedication of our team and partners to bring forward a potential new treatment option for patients with a confirmed diagnosis of COVID-19 globally,” said Michael Frank, Revive’s Chief Executive Officer. “We thank the FDA for recognizing the importance of this Phase 3 study and we are now focused on executing on our plans for initiating the clinical trial in an expeditious manner.” About the Phase 3 Confirmatory Clinical Study The Phase 3 confirmatory clinical study titled, “A Multi-Center, Randomized, Double-Blind, Placebo-Controlled Study of Bucillamine in Patients with Mild-Moderate COVID-19”, will enroll up to 1,000 patients that will be randomized 1:1:1 to receive Bucillamine 100 mg three times a day (“TID”), Bucillamine 200 mg TID or placebo TID for up to 14 days. The primary objective is to compare frequency of hospitalization or death in patients with mild-moderate COVID-19 receiving Bucillamine therapy with those receiving placebo. The primary endpoint is the proportion of patients meeting a composite endpoint of hospitalization or death from the time of first dose through Day 28 following randomization. Efficacy will be assessed by comparison of clinical outcome (death or hospitalization), disease severity using the 8-category NIAID COVID ordinal scale, supplemental oxygen use, and progression of COVID‑19 between patients receiving standard-of-care plus Bucillamine (high dose and/or low dose) and patients receiving standard-of-care plus placebo. Safety will be assessed by reported pre-treatment adverse events and treatment-emergent adverse events (including serious adverse events and adverse events of special interest), laboratory values (hematology and serum chemistry), vital signs (heart rate, respiratory rate, and temperature), and peripheral oxygen saturation. An interim analysis will be performed by an Independent Data and Safety Monitoring Board (“DSMB”) after 210 patients have been treated and followed up for a total of 28 days after randomization. The better performing Bucillamine dose at the interim analysis will be selected and patients will then be randomized 2:1 to the selected Bucillamine dose or placebo. Additional interim analyses will be performed after 400, 600, and 800 patients have reached this same post-treatment timepoint. The independent DSMB will actively monitor interim data for the ongoing safety of patients and will recommend continuation, stopping or changes to the conduct of the study based on the interim analysis reports. Scientific Rationale of Bucillamine for COVID-19 Preclinical and clinical studies have demonstrated that reactive oxygen species contribute to the destruction and programmed cell death of pulmonary epithelial cells.1 N-acetyl-cysteine (NAC) has been shown to significantly attenuate clinical symptoms in respiratory viral infections in animals and humans, primarily via donation of thiols to increase antioxidant activity of cellular glutathione2,3,4,5. Bucillamine (N-(mercapto-2-methylpropionyl)-l-cysteine) has a well-known safety profile and is prescribed in the treatment of rheumatoid arthritis in Japan and South Korea for over 30 years. Bucillamine, a cysteine derivative with two thiol groups, has been shown to be 16 times more potent as a thiol donor in vivo than NAC 6. The drug is non-toxic with high cellular permeability. The basis of the clinical study will analyze if Bucillamine has the potential, via increasing glutathione activity and other anti-inflammatory activity, to lessen the destructive consequences of SARS-CoV2 infection in the lungs and attenuate the clinical course of COVID-19. The Company is not making any express or implied claims that its product has the ability to eliminate or cure COVID-19 (SARS-2 Coronavirus) at this time.
CLong
by wealth_bakery
RVVTF REVIVE THERAPEUTICS LTD upside potentialREVIVE THERAPEUTICS has a Market Capitalization of only 27.158M, while the Net Income (FY) reveals a debt, -1.028M. Some analists predict an Average Target Price of 2.36 usd. The indicators are bullish on most timeframes. Still a lot of room to grow, with that huge volume. If you are interested to test some amazing buy and sell indicators, which give the signal at the beginning of the candle, not at the end of it, like others, just leave me a P.M.
OLong
by TopgOptions
7
Shroom Is the New WeedI've been bullish on psychedelic stocks for a while now and I really like this low hanging fruit here, RVV. Fundamentals are good and it is only a question of time before psychedelic medicine penetrates the healthcare sector with undeniable therapeutic properties. Company also boasts a nice pharma play imo. Technical (*resolution may affect drawings*): Interesting support on Fibonacci arcs . Bullish candles on (A), (B), and (C). (A) failed although it broke a bearish sequence. The stock reached support again between (B) & (C) at around $0.17. Looking forward to see what happens at the 0.786 arc (D) - but everything seems to indicate we have support if anyone thinks of jumping in now. Still cheap imo , but a pullback in the $0.20-0.25 wouldn't be surprising. Hopefully a nice catalyst is going to surface in the next weeks in order to propel the stock over the current resistance level (~$0.385). If not end of July (D) maybe end of summer. Please know this is only my opinion and I am not a financial advisor. Feel free to drop comments! Cheers
CLong
by Chasseur-Cueilleur
2